Viral Vector Vaccine by Johnson & Johnson (Janssen)
On February 27, 2021, The Food and Drug Administration (FDA) announced an Emergency Use Authorization for the Johnson & Johnson (Janssen) COVID-19 Vaccine (JNJ-78436735). This single-dose vaccine is for people 18 years old and older, and has shown to be 72% effective at preventing all COVID-19, 86% effective at preventing severe cases of the disease and protecting across countries with different variants. The Johnson & Johnson (Janssen) COVID-19 Vaccine is a viral vector vaccine that uses disabled genetic material from the common cold virus (adenovirus) so it won’t make people sick or allow the COVID-19 virus to reproduce.
The Johnson & Johnson (Janssen) vaccine is so far the only authorized vaccine specifically tested against new SARS-CoV-2 variants. According to the Emergency Use Authorization, at 28 days after a single dose it was proven 85% effective at preventing severe disease, such as hospitalization and death, from COVID-19 infection.
Download the Johnson & Johnson (Janssen) COVID-19 Vaccine to Prevent COVID-19 Fact Sheet to learn more.
mRNA Vaccine by Pfizer
On December 11, 2020, the Food and Drug Administration (FDA) announced an emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine. This vaccine is reported to be approximately 95% effective at preventing COVID-19. The two-dose vaccine claims protection is achieved 7 days after the second dose, which is delivered 21 days after the first dose, with no serious safety concerns observed.
Learn more from our FAQs and the Pfizer-BioNTech FactSheet for recipients and caregivers.
mRNA Vaccine by Moderna and the U.S. Government
Having completed Phase 3 clinical trials, this vaccine was reviewed and granted EUA status on December 18. Early results indicate it is safe and produces high levels of antibodies to the SARS-CoV-2 virus. This vaccine is also reported to be approximately 95% effective.